$127.47
▼ -0.0% Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 1
● 24
▼ 0
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Overview
52-week range
$77
$125
100% of range
Avg surprise (last 2)
+4.6%
Avg reaction (last 1)
+1.4%
100% positive
Latest IV / EM
32%
EM ±1.9% · $127 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-1.72 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $2.32 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $2.13 | $2.01 | +6.0% | — | — | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $2.22 | $2.15 | +3.3% | — | +1.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.14 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $1.87 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.35 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | BMO | -$0.26 | $2.13 | -112.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.29B | — | $17.28B | $15.81B | $15.53B | — | $16.66B | $16.11B |
| Cost of revenue | $4.20B | — | $3.85B | $3.56B | $3.42B | — | $4.08B | $3.75B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $-4.24B | — | $5.79B | $4.43B | $5.08B | — | $3.16B | $5.46B |
| EPS (diluted) | $-1.72 | — | $2.32 | $1.76 | $2.01 | — | $1.24 | $2.14 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.33B | $14.56B | $18.17B | $8.01B | $8.63B | $13.24B | $14.59B | $11.30B |
| Inventory | $6.48B | $6.66B | $6.44B | $6.60B | $6.20B | $6.11B | $6.24B | $6.47B |
| Total current assets | $35.02B | $43.52B | $47.56B | $37.06B | $35.50B | $38.78B | $40.36B | $38.20B |
| Total assets | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B | $112.63B |
| Long-term debt | $46.67B | $46.75B | $39.97B | $33.97B | $33.48B | $34.46B | $34.98B | $34.72B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $45.88B | $52.61B | $51.85B | $48.99B | $48.34B | $46.31B | $44.50B | $43.58B |